Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-14T00:45:51.427Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjuvant Tamoxifen – Longer Against Shorter (ATLAS)

Published online by Cambridge University Press:  04 December 2006

Abstract

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Adjuvant tamoxifen – longer against shorter (ATLAS). Clinical trials include:

  1. Phase III ATLAS adjuvant tamoxifen – longer against shorter: an international trial of adjuvant hormonal treatment duration (www.ctsu.ox.ac.uk/~atlas/index.html).

ATLAS – Contact Details

Country

United Kingdom

Chair

C. Williams, MRC/BHF Clinical Trial Service and Epidemiological Studies Unit, The Richard Doll Building, Roosevelt Drive, OXFORD, OX3 7LF, UNITED KINGDOM. Tel: +44 1865 743844 Fax: +44 1865 743982

Principal Investigator

C. Davies, The ATLAS Trial Office, MRC/BHF Clinical Trial Service and Epidemiology Studies Unit, The Richard Doll Building, Roosevelt Drive, OXFORD, OX3 7LF, UNITED KINGDOM. Tel: +44 1865 743840 Fax: +44 1865 743982 Email:

ATLAS Trial Office

MRC/BHF Clinical Trial Service and Epidemiology Studies Unit, The Richard Doll Building, Roosevelt Drive, OXFORD, OX3 7LF, UNITED KINGDOM. Tel: +44 1865 743844 Fax: +44 1865 743982 Email:

ATLAS – Study Details

Title

Phase III ATLAS adjuvant tamoxifen – longer against shorter: an international trial of adjuvant hormonal treatment duration (www.ctsu.ox.ac.uk/~atlas/index.html).

Coordinator(s)

Dr C. Davies, ATLAS Trial Office, MRC/BHF Clinical Trial Service and Epidemiological Studies Unit, The Richard Doll Building, Roosevelt Drive, OXFORD, OX3 7LF, UNITED KINGDOM. Tel: +44 1865 743840 Fax: +44 1865 743982 Email:

Summary

  • Opened in June 1996
  • Completed accrual in March 2005 with ~15,250 randomized
  • Follow-up to continue until at least 2010 to gather information on recurrence, second primary cancers, hospitalization and cause of death

Objective

  • To assess reliably the balance of risks of prolonging adjuvant tamoxifen by at least 5 years among women who have already had about 5 years of tamoxifen and for whom there is uncertainty about whether they should stop now, or continue for a few years longer. There were no restrictions in this trial on hormonal status, age or nodal status at the time of diagnosis with the primary eligibility criterion being substantial uncertainty about whether to stop or continue tamoxifen (see above).

Scheme

Update

  • 15,252 patients entered to date (March 2005): recruitment closed. Primary endpoint – all-cause mortality supplemented by analyses of recurrence-free survival, second primary cancers and non-fatal events leading to hospitalization. For further information, see ATLAS website (www.ctsu.ox.ac.uk/~atlas/index.html).

Related Publications

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials (The Lancet 2005; 365: 1687–1717). http://www.ctsu.ox.ac.uk/~ebctcg/

Topics

  • Tamoxifen duration
  • Tamoxifen
  • Hormonal therapy

Keywords

Large-scale randomized trial, adjuvant tamoxifen, hormonal treatment duration, survival